But "plan-design and cost-shifting will only go so far," says Joe DiBella, executive vice president at business and government insurance agency Conner Strong Cos. Inc., of Marlton, who sent me the report. DiBella said more employers were trying to impose "incentives and rewards" for quitting smoking, eating more healthfully, and needing less medical care.
'Pay-for-delay' deals
Drugmakers "increase prices to consumers by billions of dollars a year" by paying potential rivals not to make cheaper generic versions of popular medicines, warns
Michael A. Carrier, a Rutgers-Camden law school professor.
Like when the government pays farmers not to plant crops.
Carrier's been following litigation over drugmaker Bayer's past payments, of nearly $400 million, to generic drugmakers so they wouldn't make cheap antibiotics similar to its brand-name Cipro.
The New York-based U.S. Court of Appeals for the Second District had invited drug consumers to challenge past rulings that protect paid-for drug monopolies - but Wednesday, it issued a ruling that stopped that litigation.
Carrier says the bipartisan Hatch-Waxman Act, which was supposed to promote cheap generic drugs, "has been stymied by these pay-for-delay agreements."
But now, unless Congress acts, Carrier said, "the increased prescription drug prices consumers have paid are more likely to continue."
Together again
James Smart is back in business. Three years after he sold a controlling interest in Devon-based
Smart Business Advisory & Consulting Co., the largest accounting firm based in the Philadelphia area, to a Boston buyout group in a deal that valued the firm at $120 million, Smart and his old chief financial officer,
Richard Devine, have set up
Smart, Devine & Co. in the Public Ledger Building.